{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T05:27:50Z","timestamp":1777181270116,"version":"3.51.4"},"reference-count":50,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1586\/14737175.4.6.985","type":"journal-article","created":{"date-parts":[[2005,1,13]],"date-time":"2005-01-13T16:07:43Z","timestamp":1105632463000},"page":"985-993","source":"Crossref","is-referenced-by-count":13,"title":["Outcome measures for clinical trials in Parkinson\u2019s disease: achievements and shortcomings"],"prefix":"10.1586","volume":"4","author":[{"given":"Connie","family":"Marras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony E","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"CIT0002","first-page":"867","volume":"17","author":"Ramaker C","year":"2002","journal-title":"Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mow Disord"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.10473","volume":"18","author":"Movement Disorder Society Task Force on Rating Scales for Parkinson","year":"2003","journal-title":"Mow Disord"},{"key":"CIT0004","first-page":"1580","volume":"49","author":"Bennett DA","year":"1997","journal-title":"Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's disease Rating Scale. Neurology"},{"key":"CIT0006","first-page":"257","volume":"5","author":"Webster DD","year":"1968","journal-title":"Mod. Treatment"},{"key":"CIT0007","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000026244","volume":"19","author":"Mitchell SL","year":"2000","journal-title":"Neuroepidemiology"},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0168-8510(88)90058-9","volume":"10","author":"Aaronson NK","year":"1988","journal-title":"Health Pol"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/mds.10424","volume":"18","author":"Welsh M","year":"2003","journal-title":"Mov. Disord"},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/jnnp.72.2.241","volume":"72","author":"Marinus J","year":"2002","journal-title":"J NeuroL Neurosurg. Psychiatry"},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/0277-9536(92)90240-Q","volume":"35","author":"de Bruin AF","year":"1992","journal-title":"Soc. Sci. Med"},{"key":"CIT0015","first-page":"185","volume":"35","author":"Hunt SM","year":"1985","journal-title":"J. R. Coll. Gem Prac"},{"key":"CIT0016","first-page":"199","volume":"12","author":"EuroQ01 G. EuroQ","year":"1990","journal-title":"Health PoL"},{"key":"CIT0018","first-page":"203","volume":"23","author":"Kaplan RM","year":"1988","journal-title":"Health Serv. Res"},{"key":"CIT0019","first-page":"490","volume":"7","author":"Feeny D","year":"1995","journal-title":"Health Utilities Index. PharmacoEconomics"},{"key":"CIT0020","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/mds.10404","volume":"18","author":"Brefel-Courbon C","year":"2003","journal-title":"Mov Disord"},{"key":"CIT0021","first-page":"643","volume":"13","author":"Hauser RA","year":"1998","journal-title":"A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De novo Study Group. Mov. Disord"},{"key":"CIT0022","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","volume":"353","author":"The French Clozapine Parkinson Study Group","year":"1999","journal-title":"Lancet"},{"key":"CIT0024","first-page":"214","volume":"24","author":"Suchowersky O","year":"2001","journal-title":"Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD. Clin. NeuropharmacoL"},{"key":"CIT0026","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","volume":"344","author":"Freed CR","year":"2001","journal-title":"N EngL J. Med"},{"key":"CIT0027","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00002826-200105000-00003","volume":"24","author":"Clarke CE","year":"2001","journal-title":"Clin. NeuropharmacoL"},{"key":"CIT0028","first-page":"78","volume":"99","author":"Carr JA","year":"2003","journal-title":"A waitlist control-group study of cognitive, mood, and quality of life outcome after posteroventral pallidotomy in Parkinson's disease. J. Neurosurgery"},{"key":"CIT0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/jnnp.74.2.158","volume":"74","author":"Wade DT","year":"2003","journal-title":"J. NeuroL Neurosurg. Psychiatry"},{"key":"CIT0031","first-page":"1089","volume":"55","author":"Adler CH","year":"1998","journal-title":"Tolcapone Fluctuator Study Group III. Arch. NeuroL"},{"key":"CIT0032","doi-asserted-by":"crossref","first-page":"S46\u2014S53","DOI":"10.1212\/WNL.50.5_Suppl_5.S46","volume":"50","author":"Baas H","year":"1998","journal-title":"Neurology"},{"key":"CIT0033","first-page":"S39\u2014S45","volume":"50","author":"Waters CH","year":"1998","journal-title":"Tolcapone Study Group. Neurology"},{"key":"CIT0034","first-page":"858","volume":"16","author":"Koller W","year":"2001","journal-title":"Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov. Disord"},{"key":"CIT0037","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(99)03556-4","volume":"354","author":"de Bie RM","year":"1999","journal-title":"Lancet"},{"key":"CIT0038","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00006842-200005000-00012","volume":"62","author":"Pacchetti C","year":"2000","journal-title":"Psycho. Med"},{"key":"CIT0039","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00002826-200001000-00007","volume":"23","author":"Parkinson Study Group","year":"2000","journal-title":"Clin. NeuropharmacoL"},{"key":"CIT0040","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","volume":"59","author":"Parkinson Study Group","year":"2002","journal-title":"Arch. NeuroL"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.15.1931"},{"key":"CIT0042","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/berh.2000.0106","volume":"14","author":"Scott DL","year":"2000","journal-title":"Best Prac. Res. Clin. RheumatoL"},{"key":"CIT0043","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/jnnp.74.2.143","volume":"74","author":"Marras C","year":"2003","journal-title":"J. NeuroL Neurosurg. Psychiatry"},{"key":"CIT0044","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ana.410390107","volume":"39","author":"Parkinson Study Group","year":"1996","journal-title":"Ann. NeuroL"},{"key":"CIT0045","first-page":"125","volume":"278","author":"Parkinson Study Group","year":"1997","journal-title":"A randomized dose-ranging study. JAMA"},{"key":"CIT0047","first-page":"622","volume":"41","author":"Cedarbaum JM","year":"1991","journal-title":"Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology"},{"key":"CIT0049","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"Ahlskog JE","year":"2001","journal-title":"Mov. Disord"},{"key":"CIT0052","first-page":"469","volume":"307","author":"Comparisons of therapeutic effects of levodopa, levodopa, and selegiline, and bromocriptine in patients with early, mild Parkinson","year":"1993","journal-title":"Parkinson's disease Research Group in the United Kingdom. Br. Med. J"},{"key":"CIT0053","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/1531-8257(199901)14:1<69::AID-MDS1013>3.0.CO;2-M","volume":"14","author":"Melamed E","year":"1999","journal-title":"Mov. Disord"},{"key":"CIT0056","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archneur.61.4.561","volume":"61","author":"Parkinson Study Group","year":"2004","journal-title":"Arch. Neural"},{"key":"CIT0058","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJM198911163212004","volume":"321","author":"Parkinson Study Group","year":"1989","journal-title":"N Eng. J. Med"},{"key":"CIT0059","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ana.410400116","volume":"40","author":"Parkinson Study Group","year":"1996","journal-title":"Ann. Neural"},{"key":"CIT0060","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.410380512","volume":"38","author":"Olanow CW","year":"1995","journal-title":"Ann. Neural"},{"key":"CIT0061","first-page":"S160\u2014S166","volume":"44","author":"Shoulson I","year":"1998","journal-title":"Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann. Neural"},{"key":"CIT0062","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199301213280305","volume":"328","author":"The Parkinson Study Group","year":"1993","journal-title":"N Engl. J Med"},{"key":"CIT0063","first-page":"237","volume":"52","author":"Parkinson Study Group","year":"1995","journal-title":"Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch. Neural"},{"key":"CIT0068","first-page":"S68\u2014S79","volume":"184","author":"Brooks DJ","year":"2003","journal-title":"Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp. Neurol"},{"key":"CIT0069","first-page":"A82\u2014A82","volume":"58","author":"Marek K","year":"2002","journal-title":"Neurology"},{"key":"CIT0070","first-page":"A82\u2014A82","volume":"58","author":"Whone AJ","year":"2002","journal-title":"Neurology"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(04)00740-9"},{"key":"CIT0072","first-page":"93","volume":"46","author":"Sair HI","year":"2004","journal-title":"In vivo amyloid imaging in Alzheimer's disease. Neuroradiology"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14737175.4.6.985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T03:59:51Z","timestamp":1547438391000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14737175.4.6.985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,1,10]]},"published-print":{"date-parts":[[2004,11]]}},"alternative-id":["10.1586\/14737175.4.6.985"],"URL":"https:\/\/doi.org\/10.1586\/14737175.4.6.985","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}